Total patient population (n=115) | BASDAI50 responder (n=49) | BASDAI50 non-responder (n=55) | |
---|---|---|---|
Demographics | |||
Age, years±SD | 42±11 | 40±10 | 44±12 |
Male, no. (%) | 78 (68) | 34 (69) | 35 (64) |
BMI | 24.9 (22.8–27.8) | 24.1 (22.7–26.7) | 25.4 (22.7–26.9) |
Disease status | |||
Disease duration, years (median) | 8 (3–15) | 8 (3–16) | 7 (2–15) |
HLA-B27-positive, no. (%) | 95 (83) | 42 (86) | 45 (82) |
CRP, mg/L (median) | 7 (3–17) | 8 (3–18) | 6.5 (3–17) |
ESR, mm/h (median) | 25 (9–40) | 28 (14–40) | 14 (7–40) |
ASDAS CRP±SD | 3.5±1.0 | 3.4±1.0 | 3.5±1.0 |
BASDAI (median) | 6.4 (4.5–7.6) | 6.3 (4.2–7.5) | 6.6 (5.2–7.5) |
GDA VAS (median) | 7 (5–8) | 6 (5–8) | 7 (5–8) |
BASFI (median) | 5.2±2.5 | 4.5±2.6** | 5.8±2.6** |
DMARD therapy | |||
Prior biologicals, no. (%) | 21 (18.3) | 6 (12.2) | 9 (16.4) |
Methotrexate use, no. (%) | 5 (4.3) | 2 (4.1) | 2 (3.6) |
Sulfasalazine, use no. (%) | 34 (29.6) | 16 (32.7) | 16 (29.1) |
NSAID use, no. (%) | 75 (65.2) | 33 (67.3) | 36 (65.5) |
*Mean values±SD, median (IQR) or numbers (percentages) are shown.
There was a significant difference between patients with and without BASDAI50 response for **BASFI (p=0.01).
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GDA VAS, general disease activity on a visual analogue scale (0–10); HLA-B27, human leucocyte antigen B27; NSAID, non-steroid anti-inflammatory drugs.